Core Viewpoint - The company, Far East Pharmaceutical (00512), has secured exclusive commercialization rights for Neffy® (优敏速®), the world's first nasal spray epinephrine for emergency treatment of type I allergic reactions, in mainland China and non-exclusive rights in Hong Kong, marking a significant advancement in the treatment of severe allergic reactions [1][3]. Group 1: Product Development and Market Position - Neffy® is the first non-injection treatment for type I allergic reactions approved by the FDA in 35 years, utilizing an innovative nasal spray delivery method [3][6]. - The product is expected to fill a critical gap in out-of-hospital emergency scenarios, where timely administration of epinephrine is crucial for patient survival [4][6]. - The company plans to localize production within 24 months post-approval, reinforcing its leadership in the cardiovascular emergency sector [3][12]. Group 2: Clinical Need and Market Opportunity - Severe allergic reactions have a median death time of 5-30 minutes, emphasizing the need for immediate medical intervention [4]. - In China, only 25% of severe allergic reactions receive epinephrine treatment, highlighting a significant opportunity for Neffy® to improve accessibility and response times [5][7]. - The global incidence of severe allergic reactions is rising, with the Chinese market for allergy medications projected to reach $9.6 billion by 2025, indicating a growing demand for effective treatments like Neffy® [9][12]. Group 3: Competitive Advantage and Future Growth - The introduction of Neffy® enhances the company's diverse product portfolio in the cardiovascular emergency field, which includes various forms of epinephrine products [12][13]. - The company has over 30 products, with 14 included in the national emergency drug list, positioning it well to meet the needs of patients in various emergency scenarios [12][13]. - The anticipated success of Neffy® is expected to drive significant revenue growth, with projections of $540 million globally by 2025 and potential market penetration in households, schools, and travel settings [7][13].

Core Viewpoint - The company has entered into a product cooperation agreement with Youer Pharmaceutical Technology (Shanghai) Co., Ltd. to commercialize the world's first epinephrine nasal spray, Neffy® (优敏速®), for emergency treatment of type I allergic reactions in adults and children in China [1][2] Group 1: Product Cooperation and Market Potential - The agreement grants the company exclusive commercialization rights in mainland China and non-exclusive rights in Hong Kong for Neffy®, which is expected to enhance accessibility for severe allergic reaction patients [1][2] - Neffy® is the first non-injection treatment product approved by the FDA for type I allergic reactions in 35 years, filling a gap in emergency medication for out-of-hospital scenarios [2] Group 2: Company’s Strategic Focus - The company is focusing on the cardiovascular emergency sector, which includes both emergency rescue and chronic disease management, with over 30 products in its portfolio [3] - The company has a strong presence in the emergency medication market, with 14 products listed in the national emergency medication catalog and 16 in the shortage medication catalog [3] Group 3: Innovation and Development Strategy - The company emphasizes innovation and advanced technology development, aiming to meet unmet clinical needs and enhance its product pipeline through global innovation [4] - The strategy includes a dual-circulation development model that promotes both domestic and international growth, leveraging the company's industrial advantages and research capabilities [4]

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性公告 本集團引進全球首款用於治療嚴重過敏反應的腎上腺素鼻噴霧劑 -2- 此次，本集團引進的全球創新腎上腺素鼻噴霧劑優敏速®是 35 年來 FDA 首次批准的用 於 I 型過敏反應的非注射治療產品，有望提高腎上腺素治療產品對中國嚴重過敏反應患 者的可及性，並填補嚴重過敏反應急救藥物在院外場景使用的空白。待該產品上市後， 本集團將充分依託在急救領域積累的豐富科室資源與成熟的渠道體系，加速推進其學術 推廣和市場教育，助力產品快速放量。憑藉其獨特的便攜性與操作友好性，優敏速®有望 迅速滲透至家庭、學校、旅行等多種院外場景，成為本集團心腦血管急救板塊新的增長 引擎。 心腦血管急救板塊是本集團製藥科技領域重點佈局的方向之一，兼顧了急搶救與慢性疾 病管理兩大方 ...